Avra, Inc. (AVRN) Acquires Cutting Edge Equipment

ATLANTA - Jan. 10, 2022 - PRLog -- Avra, Inc. (AVRN), which recently merged with Springs Rejuvenation ("Spring"), a Chamblee, Georgia based anti-aging and stem cell center focusing on stem cell therapy, today announced that it has procured cutting edge equipment to offer treatments to a large number of low back pain sufferers that it has previously had to turn away. Acquisition of two C-arm, high definition 3D imaging for direct visualization of the injection point, will allow the Company to serve the previously unmet and growing patient pool, which should positively impact the Company's additional revenues beginning immediately upon their installation.

Low back and knee pain tops all US healthcare spending. The American Medical Association announced an estimated cost at $87.6 billion annually. With at least 1 in 4 Americans experiencing significant, chronic back pain.

Dr. Charles A. Pereyra, the founder of Springs Rejuvenation Stem Cell Therapy, said: "Springs Rejuvenation is incredibly excited to announce it will now have access one of the only stem cell products to be awarded an initial new drug (IND) status from the FDA for both knee and back pain. The new drug will utilize a Wharton's jelly matrix composed of a high concentration of both exosomes and MSC cells (undifferentiated stem cells). Signature Biologics and Chord for Life are unique in their rigorous standards for cell harvesting and laboratory quality, which have ultimately led the FDA to approve the IND."

DR. Pereyra continued: "The ability to treat back pain is a game changer. Since opening our office in Atlanta, upwards to 30-40 percent of all calls we received were requests for back pain procedures. Due to the lack of technology and product we've been unable to accommodate this patient group. Utilizing a C-arm in conjunction with an IND approved stem cell product will allow us to deliver cells directly into the area of injury.

About Springs Rejuvenation Inc.

At Springs Rejuvenation we strive to be at the cutting edge of regenerative medicine and anti-aging research. Our mission is to provide patients with individualized, state-of-the-art treatment, returning each patient to their natural mobility as quickly as possible.

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Read more: https://springsrejuvenation.com/